US Stock MarketDetailed Quotes
NRSN NeuroSense Therapeutics
- 0.770
- +0.039+5.26%
Close Jul 22 16:00 ET
13.89MMarket Cap-828P/E (TTM)
0.789High0.720Low87.77KVolume0.750Open0.732Pre Close66.38KTurnover0.67%Turnover RatioLossP/E (Static)18.04MShares2.33052wk High-1.98P/B10.08MFloat Cap0.40052wk Low--Dividend TTM13.09MShs Float8.180Historical High--Div YieldTTM9.43%Amplitude0.400Historical Low0.756Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
NeuroSense Therapeutics Stock Forum
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. ...
Neurosense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living With ALS: The Promising Results From the 12-Month Paradigm Study Highlight Primec's Potential as a Disease Modifying Drug
No comment yet